
FDA Takes Action on New Boxed Warning for Adzynma Enzyme Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Summary of the Issue
The U.S. Food and Drug Administration is alerting patients, caregivers, and health care providers that Adzynma, a recombinant ADAMTS13 enzyme replacement therapy approved for congenital thrombotic thrombocytopenic purpura (cTTP), has been associated with the development of neutralizing antibodies (blocking antibodies) that can prevent the drug from working. In serious cases, this has resulted in death, including of a 7-year-old child.
In response, the FDA has directed the manufacturer, Takeda Pharmaceuticals, to add a Boxed Warning, the most serious type of warning the FDA can require on a drug label, to Adzynma's prescribing information. This Boxed Warning alerts health care providers and patients to the risk of developing blocking antibodies and the serious consequences, including death, that may follow.
Patients currently receiving Adzynma should not stop treatment without first consulting their health care provider. Health care providers should monitor all patients with regular laboratory testing to detect blocking antibodies as early as possible.
The Public Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations. For more information, please contact us at PublicEngagement@fda.hhs.gov. For patient specific inquiries, please contact us at Patients Ask FDA.
|